学术探索
学术期刊
新闻热点
数据分析
智能评审
立即登录
IMPROVED SURVIVAL IN ADVANCED HODGKINS-DISEASE WITH THE USE OF COMBINED MODALITY THERAPY
被引:47
作者
:
BRIZEL, DM
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
BRIZEL, DM
[
1
]
WINER, EP
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
WINER, EP
[
1
]
PROSNITZ, LR
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
PROSNITZ, LR
[
1
]
SCOTT, J
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
SCOTT, J
[
1
]
CRAWFORD, J
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
CRAWFORD, J
[
1
]
MOORE, JO
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
MOORE, JO
[
1
]
GOCKERMAN, JP
论文数:
0
引用数:
0
h-index:
0
机构:
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
GOCKERMAN, JP
[
1
]
机构
:
[1]
DUKE UNIV,MED CTR,CTR COMPREHENS CANC,DIV MED ONCOL,DURHAM,NC 27710
来源
:
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
|
1990年
/ 19卷
/ 03期
关键词
:
Combined modality therapy;
Hodgkin's disease;
Involved field irradiation;
D O I
:
10.1016/0360-3016(90)90478-3
中图分类号
:
R73 [肿瘤学];
学科分类号
:
100214 ;
摘要
:
To compare the effectiveness of combined modality therapy and chemotherapy alone for the treatment of advanced Hodgkin's disease (Stages IIB-IV), records of 154 patients who achieved a complete or partial response to induction combination chemotherapy were analyzed. Sixty-seven patients received consolidation radiotherapy and 87 patients received no further treatment. Thirty of 154 patients participated in a prospective randomized trial of the Southeastern Cancer Study Group (SEG). Ten-year actuarial survival (Hodkin's disease deaths only) was 93% for the combined modality therapy patients compared with 59% for the chemotherapy alone patients (p < 0.0005). Combined modality therapy patients had an 87% 10-year actuarial freedom from relapse as opposed to 56% for the chemotherapy alone patients (p < 0.0005). Relapse occurred in 33 of the chemotherapy alone patients, 28 (85j%) being in sites involved at initial diagnosis. Seven combined modality therapy patients recured with only two true in-field failures. Multi-variate analysis demonstrated treatment (combined modality) as the only variable affecting outcome. Patients prospectively treated with combined modality therapy in the Southeastern Cancer Study Group trial also showed a statistically significant improvement in both survival and freedom from relapse compared with patients receiving chemotherapy only. There was no apparent increase in toxicity from using combined modality therapy compared with chemotherapy. Three chemotherapy patients and one combined modality patient developed acute leukemia. © 1990.
引用
收藏
页码:535 / 542
页数:8
相关论文
共 43 条
[41]
2-G
[42]
YOUNG RC, 1978, CANCER, V42, P1001, DOI 10.1002/1097-0142(197808)42:2+<1001::AID-CNCR2820420723>3.0.CO
[43]
2-Z
←
1
2
3
4
5
→
共 43 条
[41]
2-G
[42]
YOUNG RC, 1978, CANCER, V42, P1001, DOI 10.1002/1097-0142(197808)42:2+<1001::AID-CNCR2820420723>3.0.CO
[43]
2-Z
←
1
2
3
4
5
→